Beta Pharma Secures Tens of Millions in Series B Funding to Advance Carbon-14 Isotope Technology and Files IPO Prospectus

Wuxi Beita Pharmatech Co., Ltd., located in the Biomedical Accelerator of Jiangyin High-Tech Zone in Jiangsu Province, recently announced that it has completed a tens-of-millions-yuan Series B financing round led by Shenzhen Fortune Link Venture Capital Management Company Co., Ltd. The funds raised will be primarily used for technological breakthroughs in the carbon-14 (C14) field, new product development, industrialization, and the domestication and internationalization of existing labeling technologies.

Dr. Li Gang, Chairman of Wuxi Beita Pharmatech Co., Ltd. (right), and Mr. Xiang Liping, President of Shenzhen Fortune Link Venture Capital Management Company Co., Ltd. (left), successfully signed the agreement

Founded in November 2008 in the Jiangyin High-Tech Industrial Development Zone by Dr. Li Gang, a returned overseas scholar and recipient of the Second Prize of the National Science and Technology Progress Award, Beta Pharma is a high-tech private enterprise that spans several key fields, including nuclear technology applications, isotope labeling and tracing, biopharmaceuticals, and CRO services for new drug development. The company has long been dedicated to the R&D and industrialization of isotope-labeled products (such as C14 and C13) and tracing technologies. It has received numerous scientific and technological talent projects and honors, including inclusion in Wuxi’s “530” Talent Program, recognition as the “Most Promising Startup Founded by Returned Overseas Scholars,” support under the “Jiangsu Provincial Industrial Support Plan,” funding from the Ministry of Science and Technology’s Innovation Fund for Small and Medium-sized Enterprises, inclusion in the “Jiangsu Provincial Key R&D Program,” and designations as a “Jiangsu Provincial High-Tech Enterprise,” “Jiangsu Provincial Private Sci-Tech Enterprise,” host of a “Jiangsu Provincial Enterprise Academician Workstation,” and a “Wuxi City Fledgling Enterprise.” In recent years, driven by urgent market demand, the company has experienced rapid growth and has been recommended by the government as a reserve enterprise for listing on the STAR Market in Jiangyin City.

Isotope labeling and tracing is a significant aspect of the peaceful utilization of nuclear energy, representing a key contribution of the nuclear industry to pharmaceuticals, agrochemicals, environmental protection, national economic development, and public welfare. Carbon-14 (C14) is a radioactive isotope of strategic application value; it functions as a navigation and positioning system at the microscopic level, enabling researchers to elevate observational studies to the cellular, subcellular, and even molecular levels. C14-labeled products are primarily used for tracing in innovative drug development, pesticide research, biotechnology, and medical diagnostics. Due to their unparalleled detection sensitivity, these products offer unique and irreplaceable utility.

Wuxi Beita Pharmatech Co., Ltd. has established R&D institutions such as the “Nobel Prize Research Institute,” the “Academician Workstation,” and the “Isotope Labeling Engineering Technology Research Center.” After more than a decade of dedicated internal development, the company has accumulated robust expertise in isotope technology, pioneered five “gold standard” products and technologies in the pharmaceutical and healthcare sectors, and achieved the most comprehensive technological capabilities among its international peers, thereby providing reliable, high-tech services to research institutes and corporate clients. To date, it has successfully provided C14-labeled tracer technology services to dozens of listed companies and leading enterprises in innovative drug and pesticide development—including Hengrui Medicine, Hansoh Pharmaceutical, Kelun Pharmaceutical, CSPC Pharmaceutical Group, Lier Chemical, and Haier Group—as well as to research institutes such as the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), the Research Center for Eco-Environmental Sciences (Chinese Academy of Sciences), and the Shenyang Research Institute of Chemical Industry, making unique and significant contributions to the development of innovative drugs and pesticides in China, as well as to health and environmental protection initiatives.

Seizing the opportunity of this Series B financing round, Wuxi Beita Pharmatech has decisively resolved the long-standing capital shortage that had hindered its development, entering a new phase of accelerated growth. Moving forward, building on over a decade of R&D accumulation, the company will focus on strengthening its core competencies and addressing weaknesses, adhering to the principle of “rooting deeply downward and breaking through upward.” It aims to establish a distinctive C14 full industry chain while expanding into other stable isotope technologies and products, with the goal of becoming a leading global enterprise in the C14 sector and a leading domestic enterprise in the C13 sector.

Dongfang Huifu Investment Holding Co., Ltd. is a professional equity investment management institution founded by pioneers and leaders from the older generation of the securities and investment industries, together with some of China’s earliest professionals in securities and venture capital. It is a renowned private equity fund based in Shanghai. Since its establishment in 2005, the firm has forged ahead for over a decade, continuously creating legends in China’s capital markets and growing into one of the top-tier professional private fund management institutions in the country.Dongfang Huifu collaborates with governments at all levels and enterprises across China. Its more than 20 management teams nationwide oversee over 60 funds, including multiple government-guided funds, with total committed capital exceeding RMB 60 billion and paid-in capital surpassing RMB 30 billion. The company maintains joint-venture partnerships with the largest asset management and investment companies under 13 provincial governments. Its business scope covers government fund-of-funds, VC funds, PE funds, industry-specific funds, M&A funds, and distress-relief funds, enabling it to execute premier investment, merger and acquisition, and distress-relief projects. Dongfang Huifu remains steadfastly committed to facilitating industrial upgrading for local governments and fostering the growth of outstanding enterprises.